Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib alternating maintenance in mCRC
NCT05659290Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Nanfang Hospital, Southern Medical University. Started Jan 2023; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05659290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659290.